Claims for Patent: 10,814,001

Summary for Patent: 10,814,001

Title:	Oxymetazoline compositions
Abstract:	The present disclosure is directed to compositions comprising oxymetazoline and methods of stabilizing oxymetazoline compositions for long term storage.
Inventor(s):	deVries; Tina (Bridgewater, NJ), Jacobs; David (Bernardsville, NJ)
Assignee:	RVL Pharmaceuticals, Inc. (Bridgewater, NJ)
Application Number:	16/715,998
Patent Claims:	1. A single use container comprising an aqueous pharmaceutically stable ophthalmic formulation comprising: a) about 0.1 wt % oxymetazoline hydrochloride; b) about 0.64 wt % sodium chloride; c) about 0.075 wt % potassium chloride; d) about 0.048 wt % calcium chloride dihydrate; e) about 0.03 wt % magnesium chloride hexahydrate; f) about 0.39 wt % sodium acetate trihydrate and about 0.17 wt % sodium citrate; and g) about 0.5 wt % hypromellose; wherein the formulation has a pH range from about 5.8 to about 6.8, wherein the formulation has a viscosity of from about 15 cPs to about 35 cPs, wherein the formulation is stable at 25.degree. C. and 40% relative humidity for a period of at least 24 months, and wherein the formulation does not comprise a preservative. 2. The formulation of claim 1, wherein the formulation further comprises a pH adjuster selected from the group consisting of acetic acid, hydrochloric acid, sulfuric acid, fumaric acid, phosphoric acid, calcium acetate, calcium carbonate, ammonium bicarbonate, ammonium sulfate, sodium hydroxide, ammonium hydroxide, ammonium phosphate, and a combination thereof. 3. The formulation of claim 2, wherein the pH adjuster comprises hydrochloric acid. 4. The single use container of claim 1, wherein the volume of the single use container is about 0.5 mL. 5. The single use container of claim 4, wherein the single use container is in a child resistant pouch. 6. The single use container of claim 1, wherein the single use container delivers about 0.035 mg of oxymetazoline hydrochloride per drop. 7. An aqueous pharmaceutically stable ophthalmic formulation consisting of: a. about 0.1 wt % oxymetazoline hydrochloride; b. about 0.64 wt % sodium chloride; c. about 0.075 wt % potassium chloride; d. about 0.048 wt % calcium chloride dihydrate; e. about 0.03 wt % magnesium chloride hexahydrate; f. about 0.39 wt % sodium acetate trihydrate and about 0.17 wt % sodium citrate; g. about 0.5 wt % hypromellose; h. a pH adjuster; and i. water QS; wherein the formulation has a pH range from about 5.8 to about 6.8, wherein the formulation has a viscosity of from about 15 cPs to about 35 cPs and wherein the formulation is stable at 25.degree. C. and 40% relative humidity for a period of at least 24 months. 8. A single use container comprising the formulation of claim 7. 9. The single use container of claim 8, wherein the volume of the single use container is about 0.5 mL. 10. The single use container of claim 8, wherein the single use container is in child resistant packaging. 11. The single use container of claim 8, wherein the single use container delivers about 0.035 mg of oxymetazoline hydrochloride per drop. 12. A single use container comprising an aqueous pharmaceutically stable ophthalmic preservative-free formulation comprising: a. 0.1 wt % oxymetazoline hydrochloride; b. 0.64 wt % sodium chloride; c. 0.075 wt % potassium chloride; d. 0.048 wt % calcium chloride dihydrate; e. 0.03 wt % magnesium chloride hexahydrate; f. 0.39 wt % sodium acetate trihydrate and 0.17 wt % sodium citrate; and g. 0.5 wt % hypromellose; wherein the formulation has a pH range from about 5.8 to about 6.8, wherein the formulation has a viscosity of from about 15 cPs to about 35 cPs and wherein the formulation is stable at 25.degree. C. and 40% relative humidity for a period of at least 24 months. 13. The single use container of claim 1, wherein the formulation has a pH range from about 6.3 to about 6.5. 14. The formulation of claim 7, wherein the formulation has a pH range from about 6.3 to about 6.5. 15. The single use container of claim 12, wherein the formulation has a pH range from about 6.3 to about 6.5. 16. The single use container of claim 1, wherein the sodium citrate is sodium citrate dihydrate. 17. The formulation of claim 7, wherein the sodium citrate is sodium citrate dihydrate. 18. The single use container of claim 12, wherein the sodium citrate is sodium citrate dihydrate. 19. The formulation of claim 7, wherein the pH adjuster is hydrochloric acid.